NCT04547153

Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC

Infusional Fluorouracil and Weekly Docetaxel as First-line Therapy for Gastric Cancer With Bone Marrow Metastasis and Disseminated Intravascular Coagulation: a Multi-center, Phase II Trail

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A distinctive subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been described. Few patients have been treated properly due to the lack of standard care. We designed this phase II study to evaluate a dose-dense regimen for this kind of highly aggressive gastric cancer (HAGC).

Detailed description

5-fluorouracil 200mg/square metre/day continuously venous infusion on days 1-21; Docetaxel 25mg/square metre, on days 1, 8 and 15; This regimen repeats every 4 weeks.

Conditions

• Gastric Cancer
• Bone Marrow Metastasis
• Disseminated Intravascular Coagulation

Interventions

Type	Name	Description
DRUG	5-fluorouracil	200mg/square metre/day civ D1-D21
DRUG	Docetaxel	25mg/square metre ivdrip D1, D8, D15

Timeline

• Start date: 2021-01-15
• Primary completion: 2024-02-25
• Completion: 2024-03-22
• First posted: 2020-09-14
• Last updated: 2024-03-25

Locations

1 site across 1 country: China